 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug HALOPERIDOL: DO-NOT-KNOW[0m

[34mThe FDAHandler provided information indicating that HALOPERIDOL has been associated with cardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with [0m
[34mhigh doses and in predisposed patients. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol, but the evidence does not definitively determine [0m
[34mthe role of haloperidol in these cases. Additionally, elderly patients with dementia-related psychosis treated with antipsychotic drugs, including haloperidol, are at an increased risk of death. [0m
[34mHowever, it is not clear whether the increased mortality observed in studies is due to the drug itself or to characteristics of the patients.[0m

[34mThe information provided does not specifically address the risk of mortality after myocardial infarction, but it does indicate potential cardiovascular risks associated with HALOPERIDOL. Therefore, we[0m
[34mcannot definitively say whether HALOPERIDOL increases or decreases the risk of mortality after myocardial infarction based on the FDA label data.[0m
[1;34m2[0m[34m. Drug THIOTHIXENE: The FDA label for THIOTHIXENE indicates an increased risk of mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including [0m
[34mcardiovascular causes such as heart failure and sudden death. However, it does not specifically address the risk of mortality after myocardial infarction. Therefore, the information provided does not [0m
[34mconclusively determine whether THIOTHIXENE increases or decreases the risk of mortality after myocardial infarction.[0m
[1;34m3[0m[34m. Drug PIMOZIDE: DO-NOT-KNOW[0m

[34mThe FDA label for Pimozide does not specifically address the effect of Pimozide on the risk of mortality after myocardial infarction. However, it does mention that sudden, unexpected deaths have [0m
[34moccurred in patients taking high doses of Pimozide for conditions other than Touretteâ€™s Disorder, potentially due to QT interval prolongation leading to ventricular arrhythmia. This suggests a [0m
[34mpotential risk of cardiac-related adverse effects, which could theoretically affect mortality after myocardial infarction, but there is no direct evidence or specific data on mortality post-myocardial[0m
[34minfarction provided in the label.[0m
[34m                ---------[0m
[34m                Does the typical antipsychotic category of drugs increase the risk of[0m
[34m                mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDO-NOT-KNOW[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug HALOPERIDOL: DO-NOT-KNOW[0m

[34mThe FDAHandler provided information indicating that HALOPERIDOL has been associated with cardiovascular effects such as QT prolongation and/or ventricular arrhythmias, which can be more frequent with [0m
[34mhigh doses and in predisposed patients. Cases of sudden and unexpected death have been reported in association with the administration of haloperidol, but the evidence does not definitively determine [0m
[34mthe role of haloperidol in these cases. Additionally, elderly patients with dementia-related psychosis treated with antipsychotic drugs, including haloperidol, are at an increased risk of death. [0m
[34mHowever, it is not clear whether the increased mortality observed in studies is due to the drug itself or to characteristics of the patients.[0m

[34mThe information provided does not specifically address the risk of mortality after myocardial infarction, but it does indicate potential cardiovascular risks associated with HALOPERIDOL. Therefore, we[0m
[34mcannot definitively say whether HALOPERIDOL increases or decreases the risk of mortality after myocardial infarction based on the FDA label data.[0m
[1;34m2[0m[34m. Drug THIOTHIXENE: The FDA label for THIOTHIXENE indicates an increased risk of mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including [0m
[34mcardiovascular causes such as heart failure and sudden death. However, it does not specifically address the risk of mortality after myocardial infarction. Therefore, the information provided does not [0m
[34mconclusively determine whether THIOTHIXENE increases or decreases the risk of mortality after myocardial infarction.[0m
[1;34m3[0m[34m. Drug PIMOZIDE: DO-NOT-KNOW[0m

[34mThe FDA label for Pimozide does not specifically address the effect of Pimozide on the risk of mortality after myocardial infarction. However, it does mention that sudden, unexpected deaths have [0m
[34moccurred in patients taking high doses of Pimozide for conditions other than Touretteâ€™s Disorder, potentially due to QT interval prolongation leading to ventricular arrhythmia. This suggests a [0m
[34mpotential risk of cardiac-related adverse effects, which could theoretically affect mortality after myocardial infarction, but there is no direct evidence or specific data on mortality post-myocardial[0m
[34minfarction provided in the label.[0m
[34m                ---------[0m
[34m                Does the typical antipsychotic category of drugs increase the risk of[0m
[34m                mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mBased on the passages provided, there is no clear evidence linking the typical antipsychotic category of [0m
[32mdrugs directly to an increased or decreased risk of mortality after myocardial infarction. While the FDA label data for HALOPERIDOL, THIOTHIXENE, and PIMOZIDE mention cardiovascular risks and [0m
[32mincreased mortality in certain populations, such as elderly patients with dementia-related psychosis, they do not specifically address the risk of mortality after myocardial infarction. Therefore, we [0m
[32mcannot conclude that there is a clear effect of typical antipsychotic drugs on mortality post-myocardial infarction based on the available information. The reasoning is consistent with the evidence [0m
[32mprovided, and there are no apparent flaws in the reasoning process.[0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m            You MUST use the `feedback` tool/function in your next[0m
[31m            message.  If possible, send the critique you intended for[0m
[31m            the user's provided reasoning. If that is not possible or[0m
[31m            if you would simply acknowledge this message, you must[0m
[31m            instead use the `feedback` tool with `critique` set to [0m[31m""[0m[31m.[0m
[31m            [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The user's reasoning appears to be correct. There is no direct evidence provided in the passages that links the typical antipsychotic category of drugs to an increased or decreased [0m
[32mrisk of mortality after myocardial infarction. The user correctly concluded that based on the available information, there is no clear effect. Therefore, there is no flaw in the user's reasoning [0m
[32mprocess."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The user's reasoning appears to be correct. There is no direct evidence provided in the passages that links the typical antipsychotic category of drugs to an increased or decreased [0m
[34mrisk of mortality after myocardial infarction. The user correctly concluded that based on the available information, there is no clear effect. Therefore, there is no flaw in the user's reasoning [0m
[34mprocess."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The user's reasoning appears to be correct. There is no direct evidence provided in the passages that links the typical antipsychotic category of drugs to an increased or decreased [0m
[31mrisk of mortality after myocardial infarction. The user correctly concluded that based on the available information, there is no clear effect. Therefore, there is no flaw in the user's reasoning [0m
[31mprocess.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the typical antipsychotic category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for HALOPERIDOL mentions cardiovascular risks and cases of sudden death, but does not definitively determine the role of the drug in these cases, nor does it address the risk [0m
[32mafter myocardial infarction specifically."[0m[32m,[0m
[32m      [0m[32m"The FDA label for THIOTHIXENE indicates an increased risk of mortality in elderly patients with dementia-related psychosis, including cardiovascular causes, but does not specifically address [0m
[32mthe risk after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"The FDA label for PIMOZIDE mentions sudden deaths at high doses potentially due to QT interval prolongation, suggesting cardiac risks, but again does not provide specific data on mortality [0m
[32mpost-myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"None of the provided passages offer conclusive evidence to determine whether typical antipsychotic drugs as a category have a clear effect on mortality risk after myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the typical antipsychotic category of drugs on the risk of mortality after myocardial infarction based on the information provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the typical antipsychotic category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for HALOPERIDOL mentions cardiovascular risks and cases of sudden death, but does not definitively determine the role of the drug in these cases, nor does it address the risk [0m
[34mafter myocardial infarction specifically."[0m[34m,[0m
[34m      [0m[34m"The FDA label for THIOTHIXENE indicates an increased risk of mortality in elderly patients with dementia-related psychosis, including cardiovascular causes, but does not specifically address [0m
[34mthe risk after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"The FDA label for PIMOZIDE mentions sudden deaths at high doses potentially due to QT interval prolongation, suggesting cardiac risks, but again does not provide specific data on mortality [0m
[34mpost-myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"None of the provided passages offer conclusive evidence to determine whether typical antipsychotic drugs as a category have a clear effect on mortality risk after myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the typical antipsychotic category of drugs on the risk of mortality after myocardial infarction based on the information provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the typical antipsychotic category of drugs increase the risk of mortality after myocardial infarction, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for HALOPERIDOL mentions cardiovascular risks and cases of sudden death, but does not definitively determine the role of the drug in these cases, nor does it address the risk [0m
[31mafter myocardial infarction specifically.[0m
[1;31m2[0m[31m. The FDA label for THIOTHIXENE indicates an increased risk of mortality in elderly patients with dementia-related psychosis, including cardiovascular causes, but does not specifically address the [0m
[31mrisk after myocardial infarction.[0m
[1;31m3[0m[31m. The FDA label for PIMOZIDE mentions sudden deaths at high doses potentially due to QT interval prolongation, suggesting cardiac risks, but again does not provide specific data on mortality [0m
[31mpost-myocardial infarction.[0m
[1;31m4[0m[31m. [0m[3;31mNone[0m[31m of the provided passages offer conclusive evidence to determine whether typical antipsychotic drugs as a category have a clear effect on mortality risk after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the typical antipsychotic category of drugs on the risk of mortality after myocardial infarction based on the information provided.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The user's reasoning appears to be correct. There is no direct evidence provided in the passages that links the typical antipsychotic category of drugs to an increased or decreased [0m
[32mrisk of mortality after myocardial infarction. The user correctly concluded that based on the available information, there is no clear effect. Therefore, there is no flaw in the user's reasoning [0m
[32mprocess."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The user's reasoning appears to be correct. There is no direct evidence provided in the passages that links the typical antipsychotic category of drugs to an increased or decreased [0m
[34mrisk of mortality after myocardial infarction. The user correctly concluded that based on the available information, there is no clear effect. Therefore, there is no flaw in the user's reasoning [0m
[34mprocess."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The user's reasoning appears to be correct. There is no direct evidence provided in the passages that links the typical antipsychotic category of drugs to an increased or decreased [0m
[31mrisk of mortality after myocardial infarction. The user correctly concluded that based on the available information, there is no clear effect. Therefore, there is no flaw in the user's reasoning [0m
[31mprocess.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.7[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.5[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"none"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"The passages provided do not offer conclusive evidence to determine the effect of typical antipsychotic drugs on mortality risk after myocardial infarction. While cardiovascular [0m
[32mrisks and cases of sudden death are mentioned, there is no direct evidence linking these drugs to increased or decreased mortality specifically after myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-mortality after myocardial infarction-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
